GRACE :: Lung Cancer

Dr. Ravi Salgia on Management Strategies for Acquired Resistance to Targeted Therapies, Single Focus or More Diffuse

Share
download as a pdf file Download PDF

Dr. Ravi Salgia from University of Chicago explains his approach to management of acquired resistance to a targeted therapy for advanced NSCLC, both in the setting of a single area of progression and also when disease progression is more diffuse.


Leave a Reply

Ask Us, Q&A
Lung/Thoracic Cancer Expert Content

Archives

Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog

Recent Lung Blog Comments

Other Resources